University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
David M. Jablons, MD

David M. Jablons, MD

Professor in Residence, Department of Surgery, UCSF
Ada Distinguished Professorship in Thoracic Oncology, UCSF

Cancer Center Program Memberships

Experimental Therapeutics

Research Summary

I am the Ada Distinguished Professor in Thoracic Oncology and Nan T. McEvoy Distinguished Professor of Thoracic Surgical Oncology at the University of California, San Francisco (UCSF). I am also Chief of General Thoracic Surgery, Program Leader of the Thoracic Oncology Program (TOP), and Director of the Thoracic Oncology Laboratory at UCSF. I oversee a thriving bench-to-bedside program at the UCSF Helen Diller Comprehensive Cancer, comprised of thoracic surgeons, thoracic oncologists, pulmonologists, radiation oncologists, and an array of other specialists.
The Thoracic Oncology lab utilizes state-of-the-art technology such as as next-generation sequencing (NGS), synthetic chemistry, and 3D-computer simulation for assessing drug efficacy. The TOP currently offers patients a broad menu of clinical trials, testing the most promising molecularly targeted agents. In 2005, I was awarded an NIH R01 grant to investigate the role of Wnt signaling in mesothelioma, and was awarded another R01 grant in 2008 to study the role of inflammation in lung carcinogenesis. The Thoracic Oncology lab has several areas of focus including molecular therapeutics, molecular diagnostics, systems biology, systems genetics, and bench-to-bedside drug discovery. The Thoracic Oncology Lab houses one of the largest thoracic tissue bank repositories in the US, with specimens for more than 1,300 patients including fresh/frozen matched tissue (tumor, normal, serum, pbmc) for lung cancer, mesothelioma, and other cancers.
I have been a pioneer in the field of molecular diagnostics, as part of a team that developed a multi-gene diagnostic assay identifying patients at risk for recurrence of early-stage non-small-cell lung cancer. I am also a co-investigator on several other grants as part of collaborations with lead PIs in other labs: (1) Development of new immunotherapy-based drugs for the treatment of lung cancer by isolating resident immune cells in lung tumor tissue to assess the adaptive immune response; (2) Investigation of the mechanism of the KMD5A protein in rendering NSCLC resistant to EGFR TKI therapy; and (3) Investigation of the role of genetic variation in TGF-beta overactivation in COPD.

Education

Yale College, BA, 1975-79, American Literature
Albany Medical Col. of Union U, MD, 1979-84
Naval Hospital, Intern, 1984-85, Surgery
Tufts University, Resident, 1985-86, Surgery
National Cancer Institute, National Institutes of Health, Fellow, 1986-89, Surgical Oncology
Tufts University, 1989-91, Surgery
Brigham & Women's Hospital, Fellow, 1992-92, Lung Transplantation
Cornell University Medical Center, Fellow, 1991-93, Surgery


Professional Experience

  • 1993-95
    Naval Medical Center, Attending, Cardiothoracic Surgery
  • 1994-95
    University of California, San Francisco School of Medicine, Assistant Clinical Professor, Cardiothoracic Surgery
  • 1995-00
    University of California, San Francisco School of Medicine, Assistant Professor, Cardiothoracic Surgery
  • 2000-04
    University of California, San Francisco School of Medicine, Associate Professor, Cardiothoracic Surgery
  • 2004-present
    University of California, San Francisco School of Medicine, Professor, Cardiothoracic Surgery
  • 2007-present
    University of California, San Francisco School of Medicine, Ada Distinguished Professor of Thoracic Oncology Surgery
  • 1986-89
    Fleet Hospital, Lieutenant, Medical Corps, USNR Staff Surgeon
  • 1989-91
    Fleet Hospital, Lieutenant Commander, Medical Corps,USNR Staff Surgeon
  • 1991-93
    Fleet Hospital, Lieutenant Commander, Medical Corps,USNR Staff Surgeon
  • 1997-present
    UCSF Medical Center, Chief, Section of General Thoracic Surgery

Selected Publications

  1. Wang VE, Urisman A, Albacker L, Ali S, Miller V, Aggarwal R, Jablons D. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. J Immunother Cancer. 2017 Sep 19; 5(1):75.
    View on PubMed
  2. Dai Y, Jablons D, You L. Hippo pathway in lung development. J Thorac Dis. 2017 Aug; 9(8):2246-2250.
    View on PubMed
  3. Mendez P, Fang LT, Jablons DM, Kim IJ. Systematic comparison of two whole-genome amplification methods for targeted next-generation sequencing using frozen and FFPE normal and cancer tissues. Sci Rep. 2017 Jun 22; 7(1):4055.
    View on PubMed
  4. Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 May 31.
    View on PubMed
  5. Wang H, Dai YY, Zhang WQ, Hsu PC, Yang YL, Wang YC, Chan G, Au A, Xu ZD, Jiang SJ, Wang W, Jablons DM, You L. DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma. Int J Oncol. 2017 Jul; 51(1):91-103.
    View on PubMed
  6. Kratz JR, Woodard G, Jablons DM. Management of Lung Cancer Invading the Superior Sulcus. Thorac Surg Clin. 2017 May; 27(2):149-157.
    View on PubMed
  7. Dai Y, Liu S, Zhang WQ, Yang YL, Hang P, Wang H, Cheng L, Hsu PC, Wang YC, Xu Z, Jablons DM, You L. YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells. Oncotarget. 2017 Jan 17; 8(3):4096-4109.
    View on PubMed
  8. Li H, Yue D, Jin JQ, Woodard GA, Tolani B, Luh TM, Giroux-Leprieur E, Mo M, Chen Z, Che J, Zhang Z, Zhou Y, Wang L, Hao X, Jablons D, Wang C, He B. Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas. Oncotarget. 2016 Dec 06; 7(49):80415-80425.
    View on PubMed
  9. Kang HC, Kim JI, Chang HK, Woodard G, Choi YS, Ku JL, Jablons DM, Kim IJ. FAIM2, as a novel diagnostic maker and a potential therapeutic target for small-cell lung cancer and atypical carcinoid. Sci Rep. 2016 Sep 28; 6:34022.
    View on PubMed
  10. Woodard GA, Crockard JC, Clary-Macy C, Zoon-Besselink CT, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity. J Surg Oncol. 2016 Dec; 114(7):838-847.
    View on PubMed
  11. Dang J, Mendez P, Lee S, Kim JW, Yoon JH, Kim TW, Sailey CJ, Jablons DM, Kim IJ. Development of a robust DNA quality and quantity assessment qPCR assay for targeted next-generation sequencing library preparation. Int J Oncol. 2016 Oct; 49(4):1755-65.
    View on PubMed
  12. Hsu PC, You B, Yang YL, Zhang WQ, Wang YC, Xu Z, Dai Y, Liu S, Yang CT, Li H, Hu B, Jablons DM, You L. YAP promotes erlotinib resistance in human non-small cell lung cancer cells. Oncotarget. 2016 Aug 09; 7(32):51922-51933.
    View on PubMed
  13. Xu Y, Ding VW, Zhang H, Zhang X, Jablons D, He B. Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. Ther Clin Risk Manag. 2016; 12:807-16.
    View on PubMed
  14. Mendez P, Dang J, Kim JW, Lee S, Yoon JH, Kim T, Sailey CJ, Jablons DM, Kim IJ. Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories. Int J Oncol. 2016 Jul; 49(1):235-42.
    View on PubMed
  15. Hung MS, Chen IC, You L, Jablons DM, Li YC, Mao JH, Xu Z, Lung JH, Yang CT, Liu ST. Knockdown of cullin 4A inhibits growth and increases chemosensitivity in lung cancer cells. J Cell Mol Med. 2016 Jul; 20(7):1295-306.
    View on PubMed
  16. Lui NS, Yang YW, van Zante A, Buchanan P, Jablons DM, Lemjabbar-Alaoui H. SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer. PLoS One. 2016; 11(2):e0148911.
    View on PubMed
  17. Kang HC, Kim HK, Lee S, Mendez P, Kim JW, Woodard G, Yoon JH, Jen KY, Fang LT, Jones K, Jablons DM, Kim IJ. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget. 2016 Feb 16; 7(7):8321-31.
    View on PubMed
  18. Woodard GA, Jones KD, Jablons DM. Lung Cancer Staging and Prognosis. Cancer Treat Res. 2016; 170:47-75.
    View on PubMed
  19. Hung MS, Chen IC, You L, Jablons DM, Li YC, Mao JH, Xu Z, Hsieh MJ, Lin YC, Yang CT, Liu ST, Tsai YH. Knockdown of Cul4A increases chemosensitivity to gemcitabine through upregulation of TGFBI in lung cancer cells. Oncol Rep. 2015 Dec; 34(6):3187-95.
    View on PubMed
  20. Yang YL, Ni J, Hsu PC, Mao JH, Hsieh D, Xu A, Chan G, Au A, Xu Z, Jablons DM, You L. Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma. J Cell Mol Med. 2015 Oct; 19(10):2385-96.
    View on PubMed

Go to UCSF Profiles, powered by CTSI